NYSE:PRGO - Perrigo Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $74.07 -1.42 (-1.88 %) (As of 08/22/2018 03:39 AM ET)Previous Close$75.49Today's Range$73.14 - $75.0252-Week Range$67.53 - $95.93Volume1.70 million shsAverage Volume1.21 million shsMarket Capitalization$9.98 billionP/E Ratio14.99Dividend Yield1.04%Beta0.84 Company ProfileAnalyst RatingsChartDividend HistoryEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Receive PRGO News and Ratings via Email Sign-up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNYSE:PRGO CUSIP71429010 Webwww.perrigo.com Phone353-1709-4000 Debt Debt-to-Equity Ratio0.52 Current Ratio1.81 Quick Ratio1.23 Price-To-Earnings Trailing P/E Ratio14.99 Forward P/E Ratio15.21 P/E Growth2.18 Sales & Book Value Annual Sales$4.95 billion Price / Sales2.05 Cash Flow$8.1128 per share Price / Cash9.13 Book Value$43.81 per share Price / Book1.69 Profitability EPS (Most Recent Fiscal Year)$4.93 Net Income$119.60 million Net Margins4.77% Return on Equity11.92% Return on Assets6.26% Miscellaneous Employees10,400 Outstanding Shares136,830,000Market Cap$9.98 billion Perrigo (NYSE:PRGO) Frequently Asked Questions What is Perrigo's stock symbol? Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO." How often does Perrigo pay dividends? What is the dividend yield for Perrigo? Perrigo announced a quarterly dividend on Wednesday, August 1st. Investors of record on Friday, August 31st will be paid a dividend of $0.19 per share on Tuesday, September 18th. This represents a $0.76 annualized dividend and a yield of 1.03%. The ex-dividend date is Thursday, August 30th. View Perrigo's Dividend History. How were Perrigo's earnings last quarter? Perrigo Company PLC (NYSE:PRGO) announced its quarterly earnings results on Thursday, August, 9th. The company reported $1.22 EPS for the quarter, beating the Zacks' consensus estimate of $1.21 by $0.01. The firm earned $1.19 billion during the quarter, compared to the consensus estimate of $1.23 billion. Perrigo had a net margin of 4.77% and a return on equity of 11.92%. The company's quarterly revenue was down 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.22 EPS. View Perrigo's Earnings History. When is Perrigo's next earnings date? Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Perrigo. What guidance has Perrigo issued on next quarter's earnings? Perrigo updated its FY18 earnings guidance on Thursday, August, 9th. The company provided earnings per share (EPS) guidance of $4.75-4.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.21. What price target have analysts set for PRGO? 17 Wall Street analysts have issued 12-month target prices for Perrigo's stock. Their predictions range from $67.00 to $117.00. On average, they anticipate Perrigo's stock price to reach $88.6471 in the next year. This suggests a possible upside of 19.7% from the stock's current price. View Analyst Price Targets for Perrigo. What is the consensus analysts' recommendation for Perrigo? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 1 sell rating, 10 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo. Who are some of Perrigo's key competitors? Some companies that are related to Perrigo include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY). Who are Perrigo's key executives? Perrigo's management team includes the folowing people: Mr. Ronald L. Winowiecki, Chief Financial Officer (Age 52)Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 58)Mr. Sharon Kochan, Exec. VP & Pres of Consumer Healthcare International (Age 50)Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 62)Mr. Uwe F. Röehrhoff, Pres, CEO & Director (Age 56) Has Perrigo been receiving favorable news coverage? Headlines about PRGO stock have been trending positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Perrigo earned a coverage optimism score of 0.28 on Accern's scale. They also assigned press coverage about the company an impact score of 46.70 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Perrigo. Who are Perrigo's major shareholders? Perrigo's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Starboard Value LP (7.34%), BlackRock Inc. (6.38%), FMR LLC (3.73%), Victory Capital Management Inc. (2.02%), Parnassus Investments CA (1.63%) and Manning & Napier Group LLC (1.07%). Company insiders that own Perrigo stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Judy L Brown, Sharon Kochan, Svend Andersen, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo. Which institutional investors are selling Perrigo stock? PRGO stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Millennium Management LLC, Systematic Financial Management LP, Migdal Insurance & Financial Holdings Ltd., Fisher Asset Management LLC, Manning & Napier Group LLC, Point72 Asset Management L.P. and Jane Street Group LLC. Company insiders that have sold Perrigo company stock in the last year include Jeffrey Needham, John Wesolowski, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Insider Buying and Selling for Perrigo. Which institutional investors are buying Perrigo stock? PRGO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Starboard Value LP, Los Angeles Capital Management & Equity Research Inc., Victory Capital Management Inc., Marshall Wace LLP, Harel Insurance Investments & Financial Services Ltd. and Menora Mivtachim Holdings LTD.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Svend Andersen and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo. How do I buy shares of Perrigo? Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Perrigo's stock price today? One share of PRGO stock can currently be purchased for approximately $74.07. How big of a company is Perrigo? Perrigo has a market capitalization of $9.98 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe. How can I contact Perrigo? Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected] MarketBeat Community Rating for Perrigo (NYSE PRGO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 614 (Vote Outperform)Underperform Votes: 571 (Vote Underperform)Total Votes: 1,185MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/22/2018 by MarketBeat.com StaffFeatured Article: What does EPS mean?